CagriSema weight loss reached an estimated average of 12.4% in a late-stage trial involving adults with type 2 diabetes, according to Novo Nordisk. The experimental weekly injection outperformed 5 mg tirzepatide, which produced an average weight loss of 9.1% in the same study. The results came from the Phase 3 REIMAGINE 5 trial. Novo announced… Continue reading CagriSema Weight Loss Beats Tirzepatide in Diabetes Trial
CagriSema Weight Loss Beats Tirzepatide in Diabetes Trial